Tarveda Therapeutics®, Inc., today announced that the company will present results from the Phase 1 portion of a Phase 1/2a study of PEN-866 in patients with advanced solid malignancies at the European Society for Medical Oncology (ESMO) Congress 2019,
September 23, 2019
· 2 min read